[1]CurrentPatentAssignee:SAGETHERAPEUTICSINC-WO2020/243027,2020,A1Locationinpatent:Paragraph0300
[1]CurrentPatentAssignee:SAGETHERAPEUTICSINC-WO2020/243027,2020,A1
1026355-57-6
1483-56-3
107317-58-8
1018473-24-9
1210047-30-5
1214362-28-3
1214686-81-3 | Methyl morpholine-3-carboxylate-hcl | AA0014XY | MFCD09263285
1215206-78-2 | 2',3'-Dimethylbiphenyl-3-carboxylic acid | AA00155F | MFCD15143499
121679-20-7 | 1H-Indole-5-ethanesulfonamide, N-methyl-3-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)- | AA0015H8 | MFCD14636537
1217630-38-0 | (2S)-2-(2,5-Difluorophenyl)pyrrolidine | AA0015R9 | MFCD07772585
1218789-47-9 | 3-Chloro-5-(ethoxycarbonymethoxy)phenylboronic acid, pinacol ester | AA00164S | MFCD12546584
1218790-98-7 | 4-(1-Carboxycyclopropyl)phenylboronic acid, pinacol ester | AA00168G | MFCD09037838
122-95-2 | 1,4-Diethoxybenzene | AA0016GX | MFCD00015146
1221715-80-5 | 1-(3-Bromo-2-fluorophenyl)ethanol | AA0016SI | MFCD16140247
1224288-92-9 | 5-Chloropyrazolo[1,5-a]pyrimidine-3-carbonitrile | AA00174X | MFCD18073765
122647-32-9 | Methanesulfonamide, N-[4-[4-(ethylheptylamino)-1-hydroxybutyl]phenyl]-, (2E)-2-butenedioate (2:1) | AA0017IA | MFCD01715410